Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal PerspectivesLars Asphaug, Bjørn Naume, Egil Støre Blix et al.|Clinical Breast Cancer|2025Cited by 2